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Aim. Bevacizumab is a humanized recombinant monoclonal antibody that blocks vascular endothelial 
growth factor (VEGF). The activity of VEGF is the ability to promote the vascular endothelial cells 
proliferation inducing the formation of new blood vessels. Bevacizumab is used in the treatment of 
selected advanced colon, lung, renal and central nervous system tumours and plays a developing role in 
the management of breast and ovarian cancers. It is also injected intraocularly for treatment of macular 
degeneration. Recently, bevacizumab has been reported as responsible of drug-related osteonecrosis of 
the jaw (ONJ), showing a histological pattern similar to bisphosphonate-related ONJ. Moreover, it may 
increase the risk for osteonecrosis of the jaw when administered in isolation or when given concurrently 
with bisphosphonates. 
Materials and methods. Only few case reports in literature have been reported describing ONJ after 
bevacizumab administration. In June 2011, a 57-year-old female patient was referred to our department 
for pain in the left posterior mandibular region. She reported the following anamnestic data: in 2002, for 
the diagnosis of breast cancer, she underwent to left quadrantectomy and radiant treatment; from 
October 2010, she was receiving multimodal chemotherapy containing bevacizumab. No previous 
treatment with bisphosphonates, or other known local and systemic risk factors were reported. Intraoral 
examination showed a painful area of bone exposure in the left posterior lingual mandible. The 
surrounding soft tissue was erythematous with purulent discharge and with swelling of the extraoral soft 
tissue of the left mandible. After interaction with her oncologist, bevacizumab has been suspended and 
systemic antibiotic (ampicillina/sulbactam intramuscularly twice daily for 8 days and metronidazole 250 
mg per os twice daily for 8 days), local antiseptics (chlorhexidine 0.2% mouth rinses and 0.5% 
chlorhexidine gel) were administered. 
Results. After 15 days, she showed a complete healing after spontaneous sequestration of a necrotic 
bone fragment. 
Conclusions. The antiangiogenic and antiresorptive effects of bevacizumab are dose-dependent and 
time-dependent. Probably this implies that angiogenesis, bone remodelling and healing processes should 
restart after drug cessation. The present case supports the necessity to apply BRONJ prevention protocol 
also in patients in therapy with bevacizumab. 
